TABLE 5.
Outcomes, No. (%) | Multiple Myeloma ZA Interval Dosing | Prostate Cancer ZA Interval Dosing | ||||
---|---|---|---|---|---|---|
Standard (n = 21) | Extended (n = 7) | P | Standard (n = 100) | Extended (n = 28) | P | |
Skeletal-related event | 9 (43) | 1 (14) | .172 | 28 (28) | 7 (25) | .753 |
| ||||||
Osteonecrosis of jaw | 1 (5) | 0 (0) | .557 | 2 (2) | 0 (0) | .451 |
Abbreviation: ZA, zoledronic acid.